COVID-19 therapeutics I: Clinical development of our targeted SARS-CoV-2 helicase inhibitor EIS-10700 - inhibition of viral replication for COVID-19 therapy (EisCor_2).
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 16LW0012
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$9,754,346.03Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
Eisbach Bio GmbHResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable